Initial public offering

Praxis Precision Medicines Prices Public Offering of Common Stock

Friday, May 14, 2021 - 3:39am

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.
  • The gross proceeds to Praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • Praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.\nAll shares in the offering are to be sold by Praxis.
  • The public offering is being made by Praxis only by means of a prospectus relating to the offering.

Root, Inc. Technology Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Friday, May 14, 2021 - 2:36am

For years following its IPO, it was likely that Root would fail to generate positive cash flow, and Root was likely to require injections of cash to fund its operations as a result.

Key Points: 
  • For years following its IPO, it was likely that Root would fail to generate positive cash flow, and Root was likely to require injections of cash to fund its operations as a result.
  • Root touted its data-driven advantages in the marketplace, even though it\xe2\x80\x99s established industry competitors had already developed superior technology, resulting in a competitive advantage over Root.
  • Root\xe2\x80\x99s offering documents and public statements during the IPO and class period were materially misleading and false based on these facts.
  • Investors suffered damages when the market learned the truth about Root.\nA class action lawsuit has already been filed.

Monaker Group Announces Pricing of $8.1 Million Underwritten Public Offering of Common Stock

Friday, May 14, 2021 - 1:54am

333-224309) that became effective with the Securities and Exchange Commission (SEC) on July 2, 2018, the base prospectus contained therein and the accompanying prospectus supplement.

Key Points: 
  • 333-224309) that became effective with the Securities and Exchange Commission (SEC) on July 2, 2018, the base prospectus contained therein and the accompanying prospectus supplement.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC.
  • Monaker Group is a party to a definitive agreement (subject to closing conditions) to acquire HotPlay Enterprise Limited, an innovative in-game advertising and AdTech company.
  • If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.\n'

Vera Therapeutics Announces Pricing of Initial Public Offering

Friday, May 14, 2021 - 1:52am

b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.
  • The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $47.85 million.
  • All of the shares are being offered by Vera.
  • This offering is being made only by means of a written prospectus, forming a part of the effective registration statement.

Digital Brands Group, Inc. Announces Pricing of $10.0 Million Initial Public Offering and Nasdaq Listing

Friday, May 14, 2021 - 1:58am

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.

Key Points: 
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.
  • Manatt, Phelps & Phillips, LLP represented Digital Brands and Nelson Mullins Riley & Scarborough LLP acted for Kingswood.\nThe Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 (File No.
  • The Company has strategically expanded into an omnichannel brand offering these styles and content not only on-line but at selected wholesale and retail storefronts.
  • No assurance can be given that the offering will be completed on the terms described, or at all.

SAVE FOODS, INC. ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING AND NASDAQ LISTING

Thursday, May 13, 2021 - 10:50pm

Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.
  • The Offering is expected to close May 18, 2021, subject to satisfaction of customary closing conditions.
  • A final prospectus relating to this offering will be filed with the Securities and Exchange Commission.
  • Because such statements deal with future events and are based on Save Foods\xe2\x80\x99 current expectations, they are subject to various risks and uncertainties.

Flora Growth Corp. Announces Closing of Initial Public Offering

Thursday, May 13, 2021 - 10:13pm

b'TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Flora Growth Corp. (NASDAQ: FLGC) (\xe2\x80\x9cFlora\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, today announced the closing of its initial public offering of 3,333,333 of its common shares.\nOn May 11, 2021, the Company\xe2\x80\x99s common shares commenced trading on the Nasdaq Capital Market under the ticker symbol \xe2\x80\x9cFLGC".

Key Points: 
  • b'TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Flora Growth Corp. (NASDAQ: FLGC) (\xe2\x80\x9cFlora\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, today announced the closing of its initial public offering of 3,333,333 of its common shares.\nOn May 11, 2021, the Company\xe2\x80\x99s common shares commenced trading on the Nasdaq Capital Market under the ticker symbol \xe2\x80\x9cFLGC".
  • The initial public offering was priced at the high end of the proposed price range at US$5.00\xc2\xa0per share to the public for a total of\xc2\xa0US$16,666,665\xc2\xa0of gross proceeds to the Company.\nBoustead Securities, LLC acted as the sole underwriter for the offering (the \xe2\x80\x9cUnderwriter\xe2\x80\x9d) with MKM Partners acting as co-Manager.
  • As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices.
  • By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive.

Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update

Thursday, May 13, 2021 - 10:05pm

In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency.

Key Points: 
  • In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency.
  • We also established a critical cGMP manufacturing and development relationship with Catalent,\xe2\x80\x9d said Laurence Reid, Ph.D., Chief Executive Officer of Decibel.
  • Additionally, Decibel completed its Initial Public Offering (IPO) of 7,662,000 shares of common stock at a public offering price of $18.00 per share.
  • However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Thursday, May 13, 2021 - 9:01pm

b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less underwriting discounts and commissions.\nB.
  • Riley Securities, Inc. is acting as sole-book running manager for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Monaker Group Announces Proposed Public Offering of Common Stock

Thursday, May 13, 2021 - 9:05pm

b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.
  • All of the shares in the offering are being offered by Monaker.
  • In addition, Monaker expects to grant the underwriters a 45-day option to purchase up to an additional 15% of shares of its common stock on the same terms and conditions.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC.